The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1

• Type of Material: Article
• Authors: Adeiye A. Pilgrim, Emory University; Hunter C. Jonus, Emory University; Andrew Ho, Emory University; Anna C. Cole, Emory University; Jenny Shim, Emory University; Kelly Goldsmith, Emory University
• Language: English
• Date: 2023-12-31
• Publisher: TAYLOR & FRANCIS INC
• Publication Version: Final Published Version
• Copyright Statement: © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
• License: Creative Commons Attribution-NonCommercial 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1080/2162402X.2023.2240678
• Title of Journal or Parent Work: ONCOIMMUNOLOGY
• Volume: 12
• Issue: 1
• Start Page: 2240678
• End Page: 2240678
• Grant/Funding Information: This work was supported by the CURE Childhood Cancer Foundation to KCG and Atlanta Pediatric Scholars Program K12 Scholar supported by the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development grant K12HD072245 to JS.
• Keywords: PATHWAY; GANGLIOSIDE; TARGET; YAP; BONE-MARROW; Life Sciences & Biomedicine; Science & Technology; neuroblastoma; IDENTIFICATION; dinutuximab; Oncology; MUTATIONS; IMMUNOCYTOLOGICAL GD2 EXPRESSION; chemoimmunotherapy; RELAPSE; relapse; DELTA T-CELLS; >; Immunology; GD2; INTERFERON-GAMMA
• Research Categories: Health Sciences, Oncology; Health Sciences, Immunology; Biology, Cell

Abstract

Pediatric patients with high-risk neuroblastoma often relapse with chemotherapy-resistant, incurable disease. Relapsed neuroblastomas harbor chemo-resistant mesenchymal tumor cells and increased expression/activity of the transcriptional co-regulator, the Yes-Associated Protein (YAP). Patients with relapsed neuroblastoma are often treated with immunotherapy such as the anti-GD2 antibody, dinutuximab, in combination with chemotherapy. We have previously shown that YAP mediates both chemotherapy and MEK inhibitor resistance in relapsed RAS mutated neuroblastoma and so posited that YAP might also be involved in anti-GD2 antibody resistance. We now show that YAP genetic inhibition significantly enhances sensitivity of mesenchymal neuroblastomas to dinutuximab and gamma delta (γδ) T cells both in vitro and in vivo. Mechanistically, YAP inhibition induces increased GD2 cell surface expression through upregulation of ST8SIA1, the gene encoding GD3 synthase and the rate-limiting enzyme in GD2 biosynthesis. The mechanism of ST8SIA1 suppression by YAP is independent of PRRX1 expression, a mesenchymal master transcription factor, suggesting YAP may be the downstream effector of mesenchymal GD2 resistance. These results therefore identify YAP as a therapeutic target to augment GD2 immunotherapy responses in patients with neuroblastoma.